Chemotherapy | Chemoradiotherapy | ||||||
---|---|---|---|---|---|---|---|
Variable | Pre neoadjuvant | Post neoadjuvant | P a | Pre neoadjuvant | Post neoadjuvant | p a | p b |
EF (%) | 59 (56–62) | 57 (53–60) | >0.99 | 60 (57–64) | 59 (55–63) | >0.99 | 0.80 |
GS (%) | −17.6 (−16, −19) | −15.7 (−14, −17) | 0.26 | −17.3 (−16, −19) | −16.1 (−14, −18) | >0.99 | 0.59 |
MAPSE sept (cm/s) | 12.5 (11.5–13.5) | 12.1 (11.2–13.1) | >0.99 | 12.6 (11.4–13.8) | 11.1 (10.1–12.2) | 0.02 | 0.09 |
MAPSE lat (cm/s) | 11.5 (10.4–12.6) | 11.2 (10.2–12.3) | >0.99 | 11.2 (10.0–12.4) | 11.0 (9.8–12.1) | >0.99 | 0.96 |
E (cm/s) | 72.0 (62.6–81.4) | 68.1 (62.2–74.1) | >0.99 | 78.8 (68.4–89.3) | 64.1 (57.2–70.9) | 0.01 | 0.09 |
A (cm/s) | 67.8 (58.2–77.5) | 74.6 (63.9–85.3) | 0.37 | 82.0 (71.1–92.7) | 83.7 (71.6–95.9) | 0.98 | 0.41 |
E/A | 1.08 (0.93–1.25) | 0.95 (0.81–1.10) | 0.43 | 0.97 (0.82–1.14) | 0.77 (0.65–0.92) | 0.03 | 0.39 |
NT–ProBNP (ηg/l) | 93 (58–149) | 108 (70–167) | >0.99 | 65 (32–130) | 154 (92–260) | 0.05 | 0.07 |
Exercise test (W) | 150 (135–165) | 133 (115–151) | 0.03 | 151 (133–151) | 118 (96–140) | 0.001 | 0.10 |